Financial Gravity Asset Management’s Anika Therapeutics ANIK Stock Holding History

Financial Gravity Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	-$87	–	1199
2023 Q4	$87	Buy	+4	New	+$83	﹤0.01%	1095
2021 Q3	$43K	Hold	4	–	–	0.02%	619
2021 Q2	$43K	Buy	+4	New	+$170	0.02%	614
2020 Q4	$0	Buy	+4	New	+$152	﹤0.01%	480
2019 Q4	$52K	Sell	396 -7	-2%	-$407	0.04%	615
2019 Q3	$22K	Buy	403 +77	+24%	+$3.95K	0.02%	434
2019 Q2	$13K	Buy	326 +207	+174%	+$7.55K	0.01%	535
2019 Q1	$4K	Buy	+119	New	+$4.08K	﹤0.01%	722
2018 Q3	$4K	Buy	123 +15	+14%	+$593	﹤0.01%	754
2018 Q2	$4K	Buy	108 +38	+54%	+$1.56K	﹤0.01%	801
2018 Q1	$3K	Buy	+70	New	+$3.96K	﹤0.01%	824

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Financial Gravity Asset Management's ANIK Position: Q1 2024 in Review

Financial Gravity Asset Management sold out of Anika Therapeutics (ANIK) in Q1 2024, closing a stake of 4 shares — an estimated $87 sold.

Financial Gravity Asset Management first reported a position in ANIK in Q1 2018 and held it in 11 quarters. The position peaked at $52K in Q4 2019. 120 funds tracked by Wall St. Rank hold ANIK as of Q1 2024.

Financial Gravity Asset Management reported no remaining Anika Therapeutics position as of Q1 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 4 Anika Therapeutics shares in Q1 2024, an estimated $87.
Financial Gravity Asset Management first reported a position in Anika Therapeutics in Q1 2018 and held it in 11 quarters.
Financial Gravity Asset Management's Anika Therapeutics position peaked at $52K in Q4 2019.
120 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2024.

Based on Financial Gravity Asset Management's 13F filing for Q1 2024, filed 13 May 2024.